ES2734264T3 - Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol - Google Patents

Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol Download PDF

Info

Publication number
ES2734264T3
ES2734264T3 ES13834243T ES13834243T ES2734264T3 ES 2734264 T3 ES2734264 T3 ES 2734264T3 ES 13834243 T ES13834243 T ES 13834243T ES 13834243 T ES13834243 T ES 13834243T ES 2734264 T3 ES2734264 T3 ES 2734264T3
Authority
ES
Spain
Prior art keywords
pyrazol
pyridin
propyl
phenyl
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13834243T
Other languages
English (en)
Spanish (es)
Inventor
Yun Soo Bae
Hun Joo Ha
Kee In Lee
Kyung Hee Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Application granted granted Critical
Publication of ES2734264T3 publication Critical patent/ES2734264T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13834243T 2012-08-27 2013-08-02 Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol Active ES2734264T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
PCT/KR2013/006985 WO2014035070A1 (ko) 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
ES2734264T3 true ES2734264T3 (es) 2019-12-05

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13834243T Active ES2734264T3 (es) 2012-08-27 2013-08-02 Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol

Country Status (9)

Country Link
US (1) US10047067B2 (enExample)
EP (1) EP2889032B1 (enExample)
JP (1) JP5974180B2 (enExample)
KR (1) KR101633957B1 (enExample)
CN (1) CN104755077B (enExample)
ES (1) ES2734264T3 (enExample)
PL (1) PL2889032T3 (enExample)
TR (1) TR201909923T4 (enExample)
WO (1) WO2014035070A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN115427039B (zh) * 2020-04-13 2025-04-04 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびdnaナノ構造組成物ならびに方法
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119504599B (zh) * 2024-11-18 2025-09-26 安徽医科大学 一种用于治疗肾脏纤维化的吡唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
AU2697092A (en) 1991-10-08 1993-05-03 Nippon Soda Co., Ltd. Pyrazole derivative and agrohorticultural bactericide containing same
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
JP4189850B2 (ja) * 2002-05-20 2008-12-03 味の素株式会社 線維化病変組織修復剤
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
EP1900728A1 (en) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
WO2008026658A1 (ja) * 2006-09-01 2008-03-06 Otsuka Chemical Co., Ltd. N-ピリジルピペリジン化合物、その製造方法及び有害生物防除剤
KR100942382B1 (ko) 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Also Published As

Publication number Publication date
CN104755077A (zh) 2015-07-01
WO2014035070A1 (ko) 2014-03-06
JP5974180B2 (ja) 2016-08-23
KR101633957B1 (ko) 2016-06-27
US10047067B2 (en) 2018-08-14
JP2015531774A (ja) 2015-11-05
CN104755077B (zh) 2018-05-15
KR20140027833A (ko) 2014-03-07
EP2889032A1 (en) 2015-07-01
TR201909923T4 (tr) 2019-07-22
EP2889032A4 (en) 2016-03-09
US20150218125A1 (en) 2015-08-06
EP2889032B1 (en) 2019-05-08
PL2889032T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
ES2734264T3 (es) Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol
KR101630432B1 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
CN114502541A (zh) 诱导抗老化基因klotho的表达的化合物及其用途
JP2020506917A (ja) 肝疾患治療剤
KR101302315B1 (ko) 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
CN105777664B (zh) 2‑(2‑苄亚肼基)噻唑‑5‑羧酸酯及其制备方法与医药用途
MX2013009904A (es) Derivados de pirazol, metodo de preparacion de los mismos, y composicion que contiene los mismos para prevenir y tratar la osteoporosis.
ES3002189T3 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
CN115417867A (zh) 取代萘甲酰胺类衍生物及其医药用途
WO2012078519A2 (en) 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
US20040097539A1 (en) Hsp inductor
JP7085994B2 (ja) 線維症疾患の治療及び/又は予防用アミノナフトキノン化合物
CN108047160B (zh) 2-(2-苄亚肼基)-5-酰基噻唑及其医药用途
CN104546835A (zh) 3-(苯甲酰苯基)丙酸衍生物在治疗连接蛋白cx31介导的皮肤病中的应用
BR112020022220A2 (pt) novo composto e composição farmacêutica compreendendo o mesmo
CN112574160B (zh) 一种高良姜素衍生物及其制备方法和应用
CN117618422A (zh) 3-羟基-2-氨基苯并咪唑衍生物在制备防治心肌缺血再灌注损伤的药物中的应用
KR101683362B1 (ko) 소양증 개선 활성을 갖는 벤즈옥사졸 유도체
CN116157120A (zh) 包含苯并呋喃基n-酰腙衍生物的抗炎组合物
CN114315930A (zh) 化合物或其可药用盐、药物组合物及用途
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
CN115974719B (zh) 化合物、包括所述化合物的药物组合物及其用途
CN113784713A (zh) 白三烯合成抑制剂
RU2827702C1 (ru) 2,5- или 2,6-дизамещенные производные гидрохинона, содержащие по крайней мере одну карбокси-, сульфо- или амидогруппу, применяемые в качестве лекарственных средств
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用